Anuradha Krishnamurthy, MBBS

home / authors / anuradha-krishnamurthy-mbbs

Anuradha Krishnamurthy, MBBS, is a medical oncologist at Roswell Park Comprehensive Cancer Center.

Articles

Looking Ahead With TIL Therapy in Melanoma and Beyond

Looking Ahead With TIL Therapy in Melanoma and Beyond

Anuradha Krishnamurthy, MBBS
May 24th 2025

Anuradha Krishnamurthy, MBBS, discusses the exciting frontier of tumor-infiltrating lymphocyte therapy in melanoma and other disease states.

Safety Considerations With TIL Therapy

Safety Considerations With TIL Therapy

Anuradha Krishnamurthy, MBBS
May 22nd 2025

Anuradha Krishnamurthy, MBBS, discusses what physicians and patients must aware of regarding the safety of TIL therapy in melanoma.

Patient Considerations for TIL Therapy in Melanoma

Patient Considerations for TIL Therapy in Melanoma

Anuradha Krishnamurthy, MBBS
May 21st 2025
TIL Therapy: A New Era for Advanced Melanoma Treatment

TIL Therapy: A New Era for Advanced Melanoma Treatment

Anuradha Krishnamurthy, MBBS
May 21st 2025

Anuradha Krishnamurthy, MBBS, provides backgrounds on TILs and discusses their critical role in the advanced melanoma treatment landscape.

Latest Updated Articles

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC
Published: April 30th 2025 | Updated: June 25th 2025
New Standard of Care? KEYNOTE-689 Results in LA-HNSCC
DESTINY-Breast09: T-DXd Plus Pertuzumab Leads in HER2+ Breast Cancer
Published: April 21st 2025 | Updated: June 25th 2025
DESTINY-Breast09: T-DXd Plus Pertuzumab Leads in HER2+ Breast Cancer
GLP-1 Agonists Poised to Impact Breast Cancer Care
Published: September 25th 2024 | Updated: June 25th 2025
GLP-1 Agonists Poised to Impact Breast Cancer Care
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
Published: May 20th 2025 | Updated: June 4th 2025
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point
Published: May 19th 2025 | Updated: May 20th 2025
One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point
ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show